9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Theriva Biologics Files Prospectus Supplement for $2.89M Common Stock Sale
Theriva Biologics, Inc. Files Prospectus Supplement for $4.02M Stock Sale
VIRAGE trial on Nab-Paclitaxel & Gemcitabine for mPDAC
Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)
Investor Presentation
Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
News, Material Contracts
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Definitive Revised Proxy Statement
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload